Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38c13

Pathobiology

Volumn 65, Issue 2, 1997, Pages 61-68

  Kovara, Jan ^d   Stunz, Laura L ^b   Stewart, Barbara C ^c   Kriegerbeckova, Karin ^d   Ashman, Robert F ^b   Kemp, John D ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b Research Service   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Apoptosis; Deferoxamine; Iron; Lymphoma; Transferrin receptor

Indexed keywords

DEFEROXAMINE; DNA FRAGMENT; FERRIC CITRATE; IMMUNOGLOBULIN G ANTIBODY; IRON; MONOCLONAL ANTIBODY; PROPIDIUM IODIDE; TRANSFERRIN RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER THERAPY; CELL DEATH; CELL KINETICS; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; ELECTRON MICROSCOPY; IRON DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; MURINAE;

EID: 0030984734     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000164105     Document Type: Article

References (41)

1. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L: Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990:50:4929-4930.
2. Donfrancesco A, Deb G, Angioni A, Maurizio C, Cozza R, Jenkncr A, Landolfo A, Bogilno C, Helson L: D-CECaT: A breakthrough for patients with neuroblastoma. Anticancer Drugs 1993;4:317-321.
3. Kountouras J, Boura P, Karolides A, Zahariou-daki E, Tsapas G: Recombinant a2 interferon (u-IFN) with ehcmo-hormonal therapy in patients with hepatocellular carcinoma. Hepato-gastroenterology 1995:42:31-36.
4. Seligman PA, Crawford ED: Treatment of advanced transitional cell carcinoma of the bladder with continuous-inlusion gallium nitrate. J Natl Cancer Inst 1991:83:1582-1584.
5. Chitambar CR, Zahir SA, Ritch PS, Anderson T: Evaluation of continuous infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Am J Clin Oncol 1996, in press.
6. White S, Taellc R, Seligman PA, Rutherford M, Trowbridge IS: Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects. Cancer Res 1990;50:6295-6301.
7. Kemp JD, Cardillo T, Stewart BC, Kehrberg E, Weiner G, Hedlund B, Naumann P: Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res 1995,55:3817-3824.
8. Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht T, Komfeld S, Taetle R: Phase la trial of murine IgA anti-transferrin receptor antibody 42/6. Clin Cancer Res 1995; 1:1259-1265.
9. Riaz-UL HQ, Werely JP, Chitambar CR: Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp He-matol 1995:23:428-432.
10. Hileti D, Panayiotidis P, Hoffbrand AV: Iron chelators induce apoptosis in proliferating cells. Br J Haematol 1995,89:181-187.
11. Fukuchi K, Tomoyasu S, Tsuruoka N, Gomi K: Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett 1994;350:139-142.
12. Keberle H: The biochemistry of desferrioxaminc and its relation to iron metabolism. Ann N A Acad Sci 1964:119:758-788.
13. Chitambar C, Seligman P: Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells: Mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J Clin Invest 1986:78: 1538-1546.
14. Kemp JD, Thorson JA, McAlmont TH, Horowitz M, Cowdery JS, Balias ZK: Role of the transferrin receptor in lymphocyte growth: A rat IgG monoclonal antibody against the murine transferrin receptor produces highly selective inhibition of T and B cell activation protocols. J Immunol 1987;138:2422-2426.
15. Lesley J, Schulte R: Inhibition of cell growth by monoclonal antitransfcrrin receptor antibodies. Mol Cell Biol 1985:5:1814-1821.
16. Kovar J, Franck F: Growth-stimulating effect of transferrin on a hybridoma cell line: Relation to transferrin iron-transporting function. Exp Cell Res 1989:182:358-369.
17. Bergman Y, Haimovich J: Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977;7:413-417.
18. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R: Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985;4:191-209.
19. Kovar J: Growth-stimulating effect of ferric citrate on hybridoma cells: Characterization and relation to transferrin function. Hybridoma 1988;7:255-263.
20. Newell MK, Haughn LJ, Maroun CR, Julius MH: Death of mature T cells by separate ligation ofCD4and theT-ccll receptor for antigen. Nature 1990:347:286-289.
21. Kemp JD, Smith KM, Kanner LJ, Gomez F, Thorson JA, Naumann PW: Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood 1990;76:991-995.
22. Kemp JD, Thorson JA, Stewart BC, Naumann PW: Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor. Evidence for a threshold model of iron deprivation toxicity. Cancer Res 1992; 52:4144-4148.
23. Lloyd JB, Cable H, Ricc-Evans C: Evidence that desferrioxaminc cannot enter cells by passive diffusion. Biochcm Pharmacol 1991:42: 1361-1363.
24. Roberts S, Bomford A: Chelation of transferrin iron by dcsferrioxamine in K562 cells. Bio-chem J 1988:254:869-875.
25. Basset P, Quesneau Y, Zwiller J: Iron-induced LI210 cell growth: Evidence of a transferrin-independent iron transport. Cancer Res 1986; 46:1644-1647.
26. Sturrock A, Alexander J, Lamb J: Characterization of a transferrin-independent uptake system for iron in HeLa cells. J Biol Chem 1990; 265:3139.
27. Seligman PA, Kovar J, Schleicher RB, Gelfand EW: Transferrin-independent iron uptake Supports B lymphocyte growth. Blood 1991;78: 1526-1531.
28. Inman RS, Wessling-Resnick M: Characterization of transferrin-independent iron transport in K562. J Biol Chem 1993;268:8521-8528.
29. Kaplan J, Jordan I, Sturrock A: Regulation of the transferrin-independent iron transport system in cultured cells. J Biol Chem 1991;266: 2997-3004.
30. Olakanmi O, Stokes JB, Britigan BE: Acquisition of iron bound to low molecular weight chelates by human monocyte-derived macrophages. J Immunol 1994;153:2691-2703.
31. Thorstensen K, Trinder D, Aisen P: Uptake of iron from N-tcrminal half-transferrin by isolated rat hepatocytes: Evidence of transferrin-reccptor-independent iron uptake. Eur J Bio-chem 1995;232:129-133.
32. Conrad ME, Umbrcit JN, Moore EG, Uzel C, Bern MR: Alternate iron transport pathway. J Biol Chem 1994:269:7169-7173.
33. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849.
34. Kaplinsky C, Estrov Z, Freedman MJ, Gclfand EW, Cohen A: Effect of deferoxamine on DNA synthesis. DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia 1987; 1:437-441.
35. Thelander L, Graslund A, Thelander M: Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanism. Biochcm Biophys Res Commun 1983:110:859-865.
36. Lederman HM, Cohen A, Lee JWW, Freedman MH, Gelfand EW: Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984;64:748-753.
37. Wharton M, Granger DL, Durack DT: Mitochondrial iron loss from leukemia cells injured by macrophages. J Immunol 1988:141:1311.
38. Gleadle JM, Ebert BL, Firth JD, Ratcliff PJ: Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol Cell Physiol 1995:268: C1362-C1368.
39. Gleadle JM, Ebert BL, Ratcliff PJ: Diphcny-lenc iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia-implications for the mechanism of oxygen sensing. Eur J Biochcm 1995:234:92-99.
40. Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto Y: Prevention of hvp-oxia-induced cell death by Bcl-2 and Bcl-xL. Nature 1995;374:811-813.
41. Jacobson M, Raff M: Programmed cell death and Bcl-2 protection in very low oxygen. Nature 1995;374:814-816.